Novo Nordisk has doubled its insulin stockpile in the UK, amid patients’ fears that a no-deal Brexit could disrupt supplies of the life-saving medicine, its CEO has said
In normal situations Novo Nordisk, the world’s largest producer of insulin, keeps around eight weeks’ supply of the drug stockpiled in the UK at any one time
But because of Brexit this has been doubled to around 16 weeks’ supply, Fruergaard said
He told reporters at a briefing in London: “I get emails with concerns from patients who are asking about how are we going to secure the life-saving insulin that they use on an everyday basis
What we have committed to do is increase our inventory inside the UK – our products are refrigerated so there is a limit to how much you can do. But we are doubling our inventory so we have four months of supply in the UK^ (now 18 weeks supply)
In the event of a “no deal” situation, there will be time to figure out how to get supplies in, Fruergaard said